CKD in India: Year-by-Year Chronic Kidney Data (2026)

Schema Type: MedicalWebPage + Dataset

Chronic Kidney Disease has become one of India's most rapidly escalating non-communicable disease crises, yet it remains drastically underfunded and underrecognised relative to its scale. India accounts for approximately 12–17% of the global CKD burden despite representing only 18% of the world population — a disproportionate share driven by the co-epidemic of uncontrolled diabetes and hypertension that affects India more severely than most nations.

The burden of CKD is not just medical — it is economic. Renal replacement therapy (dialysis or transplant) costs ₹3–6 lakh annually per patient, and the vast majority of India's estimated 10–15 million patients requiring dialysis cannot access or afford it. Prevention and early dietary management are therefore not merely clinical priorities — they are economic and public health imperatives.

Approximately 220,000 new patients require dialysis annually in India, but only 75,000–90,000 receive it — meaning more than 60% of Indians who need renal replacement therapy cannot access it. Government schemes like Pradhan Mantri National Dialysis Programme (PMNDP) have expanded capacity, but shortfalls remain severe, particularly in Tier-3 cities and rural areas.

The cost of haemodialysis ranges from ₹300–1,200 per session, with patients typically requiring 3 sessions per week (144+ sessions per year). Even at subsidised rates, this represents ₹40,000–80,000 annually — unaffordable for the majority of CKD patients who come from lower-income groups. Every month of delayed kidney failure through dietary management directly translates to financial survival for these patients.

A 2021 systematic review in the Clinical Journal of the American Society of Nephrology documented that inorganic phosphate additives in processed food are 90–100% bioavailable compared to 40–60% for natural food phosphorus. This means processed food phosphorus is nearly twice as dangerous per milligram for CKD patients as the same amount of phosphorus in whole foods.

CKD patients who regularly consume processed food with inorganic phosphate additives may be getting 2× the effective phosphorus load compared to what any nutrition label shows, because labels list total phosphorus — not bioavailability. AaharIQ flags every inorganic phosphate additive in the ingredient list.

AaharIQ currently offers a dedicated kidney health filter that identifies: all sodium sources per serving, all phosphate additives in the ingredient list (with a flag when inorganic phosphate additives are detected), potassium content where declared on the label, and protein content per 100g and per serving.

Planned kidney health features include: a potassium calculator that estimates total daily potassium from all scanned products, a phosphate additive database mapped to Indian packaged food brands, integration with eGFR-based stage recommendations (so a Stage 3 patient gets different alerts than a Stage 1 patient), and an alert when a product is marketed as "healthy" but contains multiple kidney-stressing ingredients.

Q: Which state in India has the highest CKD burden?

Punjab (18.3%) and Andhra Pradesh (17.8%) show the highest documented CKD prevalence. Punjab's burden is driven by a combination of agricultural chemical exposure (organophosphate pesticides) and high diabetes prevalence. Andhra Pradesh faces both the highest diabetes burden in India and documented environmental nephrotoxins including fluoride-contaminated water in certain districts.

Q: How many Indians are on dialysis?

Approximately 75,000–90,000 Indians receive regular dialysis, out of an estimated 220,000 new patients who need it annually. The rest — over 130,000 new patients each year — cannot access renal replacement therapy due to cost, distance, or availability constraints. Peritoneal dialysis is available to approximately 5,000–8,000 patients.

Q: What is the main cause of kidney failure in India?

Diabetes mellitus (40–42%) and hypertension (25–30%) together account for 65–72% of all CKD cases in India — reflecting the country's twin epidemics of both conditions. Glomerulonephritis (immune-mediated) accounts for another 10–15%. Agricultural nephropathy (from pesticide and heavy metal exposure) is a significant but underquantified cause in farming communities.

Beyond the diabetes- and hypertension-driven CKD cases covered elsewhere in this guide, India is home to one of the world's notable regional clusters of chronic kidney disease of unknown etiology (CKDu) — a distinct condition first documented in the Uddanam region of Andhra Pradesh, spanning coastal Srikakulam district and parts of Prakasam district. By 2015, an estimated 34,000 people in this region had been diagnosed with CKD, with roughly 4,500 associated deaths, earning the condition the regional name "Uddanam nephropathy." Similar CKDu clusters have since been identified in Odisha, Goa, and Maharashtra. What distinguishes CKDu from the standard CKD progression covered elsewhere in this guide is its clinical profile — it predominantly affects male agricultural workers, often without the significant proteinuria or hypertension that typically accompanies diabetes- or hypertension-driven kidney disease, and kidney biopsies characteristically show chronic tubulointerstitial nephritis, a pattern of damage distinct from diabetic or hypertensive nephropathy. The exact cause remains genuinely unresolved despite considerable research — proposed factors include chronic heat stress and dehydration from outdoor agricultural labour, agrochemical exposure, and contaminated drinking water, though several individual heavy-metal and pesticide hypotheses have failed to show consistent association across studies, making this a genuinely multifactorial and still-investigated public health puzzle rather than a solved case with a single clear cause. Continued research funding into this specific cluster remains a genuine public health priority. Awareness.

A more directly preventable contributor to India's CKD burden, and one with genuine relevance to everyday behaviour rather than occupational or regional exposure, is the widespread pattern of self-medicated NSAID (non-steroidal anti-inflammatory drug) use for routine pain — headaches, joint pain, and general aches — often without medical supervision or awareness of cumulative kidney risk. NSAIDs, including common over-the-counter painkillers, reduce blood flow to the kidneys through their effect on prostaglandin synthesis, and sustained, frequent use over months or years is a well-documented contributor to progressive kidney damage, an effect that compounds considerably for anyone already managing diabetes, hypertension, or existing reduced kidney function from any cause. India's relatively easy over-the-counter access to many analgesics, combined with limited public awareness that a substance sold without prescription can still carry meaningful long-term organ risk with regular use, makes this a genuinely underappreciated and preventable piece of the country's overall CKD picture. For anyone using pain medication regularly rather than occasionally — particularly alongside an existing diabetes or hypertension diagnosis — discussing safer, kidney-conscious pain management alternatives with a doctor is a reasonable, concrete step that sits entirely within an individual's own control, unlike many of the other risk factors covered throughout this guide. Reading medication labels for kidney-related warnings, rather than assuming any over-the-counter product is automatically risk-free with regular use, is a habit worth building. A small habit with real protective value. Simple.

A persistent and genuinely risky misconception around CKD dietary management is that protein restriction should be applied uniformly and aggressively regardless of disease stage — when in fact appropriate protein intake varies considerably across the five recognised CKD stages (categorised by estimated glomerular filtration rate, or eGFR, ranging from normal function in Stage 1 down to kidney failure in Stage 5) and the specific clinical situation. In earlier CKD stages, moderate protein restriction can genuinely help slow disease progression by reducing the kidneys' filtration workload, but excessive or poorly managed restriction risks a different, serious problem: protein-energy wasting, a state of malnutrition and muscle loss that research has independently linked to worse outcomes in CKD patients, including higher mortality. For patients on dialysis specifically, protein needs actually increase rather than decrease, since the dialysis process itself removes amino acids and protein from the blood, meaning the aggressive restriction appropriate for earlier-stage CKD can become actively harmful once a patient progresses to dialysis. This stage-dependent complexity is precisely why CKD dietary management, more than almost any other condition covered on this site, requires individualised guidance from a nephrologist or renal dietitian rather than generic "low protein" advice applied uniformly — a self-directed protein restriction based on general internet advice, without professional guidance matched to actual CKD stage, carries genuine risk of doing more harm than good. Professional guidance, matched to actual stage, is the only safe way to navigate this. Never self-adjust protein intake based on generic online advice alone.

Estimated glomerular filtration rate (eGFR) is the specific laboratory measure that determines which of the five CKD stages referenced throughout this guide a patient actually falls into, and understanding roughly what the number means makes lab reports considerably less intimidating. eGFR estimates how much blood the kidneys filter per minute, calculated from a blood creatinine measurement combined with age, sex, and sometimes body size — a healthy young adult typically shows an eGFR of 90 or above. Stage 1 CKD reflects normal or high eGFR (90+) but with other evidence of kidney damage, such as protein in the urine; Stage 2 covers mildly reduced function (eGFR 60-89); Stage 3, often the point at which CKD is first diagnosed since earlier stages frequently produce no symptoms, splits into 3a (45-59) and 3b (30-44); Stage 4 reflects severely reduced function (eGFR 15-29); and Stage 5, sometimes called kidney failure or end-stage renal disease, is eGFR below 15, typically requiring dialysis or transplant. Because CKD frequently produces no noticeable symptoms until relatively advanced stages, routine eGFR testing — particularly for anyone with diabetes, hypertension, or a family history of kidney disease, the primary risk factors covered elsewhere in this guide — remains the only reliable way to catch declining kidney function early enough for the stage-appropriate dietary and medical interventions covered throughout this site to have the best chance of slowing progression. A routine annual blood test, requested proactively, is a small step that catches this silent decline while intervention still has the most room to help. Ask for it by name at your next check-up. Worth it.